Balhimycin
Also known as: A82846B analog, Amycolatopsis balhimycina antibiotic, Balhimycin, Balhimycin A
Source Balhimycin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Balhimycin is a glycopeptide antibiotic produced by the actinomycete Amycolatopsis balhimycina. It belongs to the family of glycopeptide antibiotics and is investigated primarily for its activity against Gram‑positive bacteria such as methicillin‑resistant Staphylococcus aureus (MRSA). The compound remains in the research stage, with no approved therapeutic use, and is of interest for both its antibacterial potential and as a model for biosynthetic engineering.
Mechanism of Action
The cited literature does not provide a detailed molecular description of balhimycin’s antibacterial mechanism. While it is classified as a glycopeptide antibiotic, the specific target(s) and pathway(s) by which balhimycin inhibits bacterial growth are not outlined in the referenced abstracts.
What the Research Shows
Balhimycin has been studied mainly as a model for natural‑product biosynthesis and metabolic engineering. Sequencing of its biosynthetic gene cluster revealed incorporation of unusual phenylglycine residues. Synthetic‑biology approaches have been used to manipulate precursor supply and improve yields, as described in several studies that engineered the producing strain Amycolatopsis balhimycina. A genome‑scale metabolic model of the organism identified key reactions for enhanced production. Structural work has resolved the three‑dimensional crystal structure of balhimycin, providing insight into its conformation. An essay on drug‑induced platelet apoptosis noted that balhimycin can trigger platelet apoptosis in vitro, suggesting a potential hematologic toxicity.
Reported Benefits
Preclinical investigations indicate that balhimycin possesses activity against resistant Gram‑positive pathogens, supporting its classification as a glycopeptide antibiotic. The compound serves as a valuable scaffold for studying phenylglycine‑containing peptides and for developing engineered strains that produce higher antibiotic yields, which could facilitate the discovery of novel glycopeptide derivatives.
Limitations of the Evidence
Natural production of balhimycin is low, necessitating extensive metabolic‑engineering efforts to obtain usable quantities. No clinical trials or regulatory approvals have been reported, so its efficacy and safety in humans remain untested. Toxicity data are limited to in‑vitro observations of platelet apoptosis, and broader safety profiles are lacking.
Safety Considerations
An essay on pharmacotoxicology reported that balhimycin can induce platelet apoptosis, a mechanism that may contribute to drug‑induced thrombocytopenia. This finding highlights a potential hematologic risk that would require careful evaluation in any future therapeutic development. Apart from this, no systematic adverse‑event data are available.
How It Is Administered
Balhimycin is currently confined to laboratory research; no approved formulation or route of administration has been described in the literature. Studies have focused on production in bacterial cultures and structural analysis rather than clinical delivery.
Routes of Administration
Goals & Uses
- Antibiotic resistance mechanism studyBasic ScienceModerate
- Glycopeptide biosynthesis elucidationBasic ScienceHigh
- Treatment of multidrug‑resistant Gram‑positive infectionsAntibacterial TherapyModerate
- Gram-positive bacterial infection researchAntimicrobial ResearchLow
Contraindications
- Known hypersensitivity to glycopeptide antibioticsAllergyHigh
Adverse Effects
- Red man syndromeInfusion ReactionUnknown
- NephrotoxicityRenalUnknown
Drug Interactions
- AminoglycosidesModerate
Population Constraints
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionInvestigationalUnder clinical evaluation; not authorized for marketing.
- United StatesInvestigationalOnly available under IND for clinical trials.
- United KingdomUnapprovedNo MHRA approval; research compound only.
Not approved for human use in any jurisdiction; limited to pre‑clinical and early‑phase clinical investigations.
Evidence & Sources
- Journal ArticleModerateAl Toma RS, et al.2015-01-01T00:00:00.000000Z
- Journal ArticleModerateWohlleben W, et al.2012-01-01T00:00:00.000000Z
- Journal ArticleModerateThushara RM, et al.2014-01-01T00:00:00.000000Z
- Journal ArticleModerateBilyk O, Luzhetskyy A2016-01-01T00:00:00.000000Z
- Journal ArticleLowVongsangnak W, et al.2012-01-01T00:00:00.000000Z
- Journal ArticleModerateMarraud M, Aubry A1996-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of organism produces balhimycin?
Balhimycin is naturally synthesized by the actinomycete Amycolatopsis balhimycina, a soil‑derived bacterium known for producing glycopeptide antibiotics.
Has balhimycin been tested in patients?
No. All available reports describe preclinical work, biosynthetic engineering, and in‑vitro studies; there are no clinical trial data or regulatory approvals.
Why is balhimycin of interest to researchers?
It contains unusual phenylglycine residues, serves as a model for glycopeptide biosynthesis, and its production can be enhanced through metabolic engineering, offering insights for novel antibiotic development.
What safety concerns have been identified?
One review noted that balhimycin can trigger platelet apoptosis, suggesting a risk of thrombocytopenia. Comprehensive safety evaluations have not yet been performed.
Can balhimycin be obtained for laboratory use?
Balhimycin is produced in research laboratories by culturing Amycolatopsis balhimycina or engineered strains; commercial pharmaceutical formulations are not available.
What is Balhimycin?
Balhimycin is a glycopeptide antibiotic produced by the actinomycete Amycolatopsis balhimycina. It belongs to the family of glycopeptide antibiotics and is investigated primarily for its activity against Gram‑positive bacteria such as methicillin‑resistant Staphylococcus aureus (MRSA). The compound remains in the research stage, with no approved therapeutic use, and is of interest for both its antibacterial potential and as a model for biosynthetic engineering.
What is Balhimycin used for?
Balhimycin is educationally associated with: Antibiotic resistance mechanism study, Glycopeptide biosynthesis elucidation, Treatment of multidrug‑resistant Gram‑positive infections, Gram-positive bacterial infection research. Educational only — not medical advice.
How is Balhimycin administered?
Recorded routes of administration: Intramuscular, Intravenous, Topical.
What are the potential side effects of Balhimycin?
Reported adverse effects include: Red man syndrome, Nephrotoxicity. This list is not exhaustive — consult a qualified clinician.
Who should avoid Balhimycin?
Recorded contraindications: Known hypersensitivity to glycopeptide antibiotics. Consult a qualified clinician before use.